Tiziana Life Sciences’ Post

The video Mark mentions below is great to learn more about protein degradation!

Thanks again all for attending the event! Please keep eyes on the further communication for the next webinar event "Mastering Non-Clinical Challenges in Drug Development: A Roadmap to Success"

On Rare Disease Day, we send our congratulations to the PharmAust team on the recently released top line results from their Phase 1 MEND study, assessing monepantel as a potential therapy for Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS). This work has found that "monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®", while "preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R". More detail on these results can be found in the below presentation, delivered by PharmAust CEO, Dr Michael Thurn. Alithia Life Sciences is extremely proud to be associated with this groundbreaking research and we look forward to supporting future phases of this study when they commence in the second half of 2024. #rarediseaseday #raredisease #rarediseases #motorneuronedisease #mnd #als #clinicalresearch #clinicaltrial #medicalresearch #scientificresearch #medicaltreatment

“Q4 of 2023 and 2024 will be pivotal for Cybin as we expect topline clinical data readouts from both our Phase 1/2a trial of CYB003 — our deuterated psilocybin analog — and from our Phase 1 trial of CYB004 and SPL028: our deuterated DMT programs," said Cybin CEO Doug Drysdale   "Cybin now has access to over US$100 million, capital expected to provide the cash runway needed to complete these value-driving clinical milestones and to continue focusing on clinical execution with the ultimate goal of bringing improved therapeutic options to patients in need." Learn more: https://lnkd.in/dpdi8BJt #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth

At STATinMED, we're leaders in the field of #realworldevidence, and we have the publications to prove it. Check out our 1,000+ life science publications and presentations spanning a number of the industry's top journals: https://lnkd.in/gPpviMP2 #realworlddata #lifescience #healthcare #HEOR #outcomesresearch #dataanalytics

At @Bristol Myers Squibb, we are all in on #TargetedProteinDegradation (TPD) and its potential for patients. As one of our differentiated research platforms, we’re expanding on our legacy in TPD by exploring potential new options across a broad range of diseases. We had great discussions about these advancements during our annual European Scientific Innovation Summit this week. You can learn more about our efforts in TPD here: Science Firsthand: The pathway to drug discovery – Bristol Myers Squibb (bms.com) #BMS_Employee, #EUScientificInnovationSummit

🎙 The cost of bringing assets to the Life Sciences market has reached an all-time high, but more than a third of all new launches fail to meet expectations. In our latest Life Sciences in the Spotlight episode, Niamh O'Donnell had a chat with Adrian Harrington of Biogen to dive deeper into the evolution of market access today, plus the trends and challenges of tomorrow.   They discuss what excellent market access means, how to navigate the challenging payer environment, the top three actions to deliver market access excellence of tomorrow and look ahead to what the key drivers of success for pharma companies will be.   Listen the full episode or read the transcript on our website here: https://lnkd.in/gfc6GmP4 #marketaccess #lifesciences #pharma #pharmabuyer #futureofhealth

Great conference! I have a lot of suggestions in using mass spec to identify unknowns. Including "spectraless" databases such as CAS and ChemSpider and NIST Hybrid searches. See my presentation https://lnkd.in/gFH_MVz8

Targeted Protein Degradation (TPD) has the potential to reshape the expectations of what is possible for many types of diseases by unlocking therapeutic targets previously deemed undruggable.     I believe it critical that we come together as an industry to share ideas and best practices to help accelerate the delivery of safe and effective protein degraders. That is why I was delighted to attend the 6th Annual TPD Summit in Boston, MA, to connect with other industry leaders and share invaluable insights. The conference reaffirmed how rapidly this field is advancing as a promising new modality, with an increasing number of clinical trials and developers focused on TPD. It was a privilege to share the progress @AstellasPharma is making in advancing a novel KRAS degrader with exciting first-in-class potential and discussing the speed with which we are advancing this program.     TPD is a promising technology that may bring a new era to the field of synthetic drug development. I am committed to leveraging our collective knowledge and collaborating with expert partners as we work to advance this exciting technology and create VALUE for patients around the globe.    #ScienceFirstForPatients #ChangingTomorrow #TargetedProteinDegradation 

⚫️ Now at ASCRO, Uppsala: Martin Bergstrand explains the possibilities of Model Informed Drug Development, how it can reduce time to market, cost, size of study population and increase probability of success in dose selection, formulation and route of administration among other things, to an engaged audience from different Clinical Research Organizations, (CRO). 🟠 And a tip: There are still (very) few seats left to a workshop on the topic, “An introduction to probabilistic decision support in drug development”, in Rome during PAGE, led by Martin, our CEO Peter Milligan, Chief statistician Richard Anziano and Senior Consultant Giovanni Smania. #cro #lifesciences #biosimulation #biotech